KNOREX LTD. Class A Ordinary Shares (KNRX)

KNOREX Ltd. (NYSE American: KNRX) (“KNOREX” or the “Company”), a leading provider of AI-driven cross-channel advertising technology solutions, today advised that its Financial Statements included in its Annual Report on Form 20F for the year ended December 31, 2025, contained an audit report from its Independent Registered Public Accounting Firm with an explanatory paragraph emphasizing that the Consolidated Financial Statements were prepared assuming that the Company will continue as a going concern. Release of this information is required by Section 610(b) of the NYSE American Company Guide and does not reflect any change or amendment to any of the Company’s filings for the fiscal year ended December 31, 2025.

KNOREX Ltd. (NYSE American: KNRX) (“KNOREX” or the “Company”), a leading provider of AI-driven cross-channel advertising technology solutions, today provided a business update and reported financial results for the fiscal year ended December 31, 2025. The Company previously disclosed that it required additional time to complete its year-end reporting process following its transition to a U.S. public company. The 20-F filing has now been completed and is available on the SEC's website at www.sec.gov.

Artificial Intelligence is rapidly transforming drug discovery, clinical research , and Alzheimer's disease development, and IGC Pharma, Inc. (NYSE: IGC) is positioning itself at the forefront of that evolution. The clinical-stage biotechnology company will present seven scientific papers at the Alzheimer's Association International Conference (AAIC) 2026 in London, July 12-15, highlighting a growing portfolio of AI-powered healthcare technologies designed to accelerate Alzheimer's drug development , improve clinical trials , and enhance precision medicine .

KNOREX Ltd. (NYSE:KNRX) (“KNOREX” or the “Company”), a leading provider of AI-driven advertising technology solutions, today announced that it received a notice from NYSE Regulation on May 18, 2026 indicating that the Company is not in compliance with the continued listing standards of NYSE American LLC (“NYSE American” or the “Exchange”). The Company filed a Form 12b-25 (the “NT 20-F”), which extended the due date for the Company’s annual report on Form 20-F for the fiscal year ended December 31, 2025 (the “2025 Form 20-F”) to May 15, 2026. The Company failed to timely file its 2025 Form 20-F by the extended filing due date of May 15, 2026 (the “Filing Delinquency”). The Company is now subject to the procedures and requirements set forth in Section 1007 of the NYSE American Company Guide.

KNOREX Ltd. (NYSE American: KNRX) (“KNOREX” or the “Company”), a leading provider of AI-driven advertising technology solutions, today announced major advancements to its KNOREX XPO℠ platform. The update introduces an AI-powered Keyword Optimizer for Google Ads and a sophisticated Machine Learning-based Data-Driven Attribution (DDA) model for Meta, Google, TikTok, and other major native platforms. The enhancements are designed to help advertisers improve return on investment, reduce customer acquisition costs, and drive more efficient campaign performance.

KNOREX Ltd. (NYSE American: KNRX) (“KNOREX” or the “Company”), a leading provider of AI-driven programmatic advertising solutions, today announced the full-scale commercial deployment of major enhancements to KNOREX KAIROS™ after more than six months of selective deployments, the Company’s proprietary artificial intelligence decisioning infrastructure powering bid optimization and performance modeling within the KNOREX XPO™ platform.

KNOREX Ltd. (NYSE American: KNRX) ("KNOREX" or the "Company"), a leading provider of AI-driven programmatic advertising solutions, today announced partnering with a performance-driven legal marketing firm to conduct a nationwide campaign designed to connect high-intent individuals with law firms across the U.S. The primary objective was to generate a robust pipeline of qualified leads that convert into signed legal retainers, while maintaining strong cost efficiency and scalable performance.

KNOREX Ltd. (NYSE American: KNRX) ("KNOREX" or the "Company"), a leading provider of AI-driven programmatic advertising solutions, today announced results from a large-scale automotive campaign demonstrating how its unified AI-powered XPO platform converts national digital awareness campaigns into dealership visits at scale.

In a market searching for asymmetric upside, ENDRA Life Sciences (NASDAQ: NDRA) is quietly building one of the more compelling dual-engine growth narratives in the small-cap space. The company sits at the intersection of two powerful trends: breakthrough liver imaging technology and next-generation treasury strategy exposure to high-momentum digital assets like HYPE .

KNOREX Ltd. (NYSE American: KNRX) (“KNOREX” or the “Company”), a leading provider of AI-driven programmatic online advertising products and solutions, today announced the launch of its agentic AI-ready KNOREX Ads API, designed to serve as a foundational infrastructure layer for AI-native, cross-channel advertising workflows.